Table 2.
Outcomes and toxicities of increasing BED on outcomes for prostate cancer radiotherapy among EBRT trials.
| 5-year values | 10-year values | |||||||
|---|---|---|---|---|---|---|---|---|
| Outcomes | % range | % value if slope is near 0 |
Slope (p-value) | % range | % value if slope is near 0 |
Slope (p-value) | ||
| Biochemical | FFBF low-risk | 70-100 | 5.5 (0.04) | 45-90 | 9.6 (<0.01) | |||
| FFBF intermediate-risk | 70-95 | 5.3 (<0.01) | 40-60 | 7.2 (0.01) | ||||
| FFBF high-risk | 40-80 | 7.5 (<0.01) | 20-50 | 5.8 (0.10) | ||||
| Patient overall | OS | 82-97 | 87 | −0.2 (0.60) | 66-83 | 71 | 0.7 (0.34) | |
| DM | 1-14 | 4 | 0.2 (0.66) | † | † | † | ||
| CSM | 0-8 | 2 | −0.1 (0.68) | 1-14 | 5 | 0.1 (0.87) | ||
| Toxicities (RTOG) | Range | Slope (p-value) | ||||||
| Acute (BED10) | GU | 3D-CRT | 0-13 | 5 | −0.3 (0.76) | |||
| IMRT | 0-8 | 4 | 5.4 (0.47) | |||||
| GI | 3D-CRT | 0-6 | 2 | −1.0 (0.19) | ||||
| IMRT | 0-3 | 2 | 1.0 (0.73) | |||||
| Late (BED3) | GU | 3D-CRT | 0-13 | 5 | 0.4 (0.31) | |||
| IMRT | 0-4 | 3 | 0.4 (0.71) | |||||
| GI | 3D-CRT | 0-10 | 1.5 (<0.01) | |||||
| IMRT | 1-3 | 2 | −0.2 (0.60) | |||||
Abbreviations: 3D-CRT: 3 dimensional conformal radiation therapy; BED: biologically equivalent dose; CSM: cancer specific mortality; DM: distant metastasis; FFBF: freedom from biochemical failure; GI: gastrointestinal; GU: genitourinary; IMRT: intensity modulated radiation therapy; OS: overall survival; RTOG: Radiation Therapy Oncology Group
Note:
†
denotes insufficient data reported
p-values < 0.05 are boldfaced.